Skip to content
Search

Latest Stories

Industry body submits CBD novel food application for validation by Food Standards Agency

The Association for the Cannabinoid Industry (ACI) has submitted its novel food application to the FSA on behalf of CBD manufacturers.

This marks a pivotal milestone for the ACI as it met the compliance deadline set by the UK’s Food Standards Agency (FSA), the association said in an update on Tuesday (Feb 16).


“I am delighted to submit these dossiers on behalf of the ACI-ADSL CBD safety consortium and support an industry on the cusp of transitioning from a grey area to a fully legally compliant market,” said Dr Parveen Bhatarah, regulatory and compliance associate of the ACI who led the effort.

Up until now there were some fundamental unanswered questions regarding the safety of CBD for human consumption including concerns raised by the government’s Committee on Toxicology (CoT).

In February 2019, CBD was classified by the European Food Standards Agency (EFSA) as a ‘novel food’, meaning that safety studies were required for CBD products to ensure they were safe for human consumption.

In February, the FSA set a deadline of March 31, 2021 for the industry in response to the EFSA’s classification. On this date, CBD companies wishing to stay in the UK market would need to have their application validated by the FSA, or face their products being removed from shelves.

In response to this deadline, the ACI partnered with Advanced Development and Safety Laboratory (ADSL), to announce the launch of a landmark study in last September with a consortium of CBD companies committed to building a sustainable, safe and fully compliant industry in the UK.

“The FSA have always had an ethical responsibility to gain evidence to prove that CBD is safe for human consumption. With the submission of the ACI and ADSL CBD consortium safety study we are well on the way to providing them this evidence,” says Dr Paul Duffy, toxicology associate, ACI.

More For You

NICE approves AstraZeneca’s twice-a-day tablet ‘capivasertib’ for advanced breast cancer

HR-positive, HER2-negative advanced breast cancer is currently incurable, and treatment aims to slow progression and prolong life

Gettyimages

NICE approves twice-a-day tablet for advanced breast cancer

Every year, thousands of people with hormone receptor (HR)-positive HER2-negative breast cancer could benefit from a new twice-a-day tablet, now set to be funded immediately through the Cancer Drugs Fund.

The National Institute for Health and Care Excellence (NICE) has approved the use of capivasertib (also known as Truqap), in combination with fulvestrant, as an option for around 1,100 adults with HR-positive HER2-negative breast cancer that has certain genetic mutations and has spread.

Keep ReadingShow less
ABPI and government fast-track VPAG scheme review to address high medicine payment rates

The 2025 VPAG payment rate for newer medicines has been set at 22.9 per cent.

Photo credit: gettyimages

Review of 2024 VPAG scheme to be completed by June

The Association of the British Pharmaceutical Industry (ABPI) and the government have agreed to bring forward a planned review of the 2024 Voluntary Scheme for Branded Medicines Pricing, Access, and Growth (VPAG), originally scheduled for autumn 2025.

The review is expected to be completed in June 2025, aligning with the anticipated release of the government’s 10-year NHS Plan and the Life Sciences Sector Plan as part of the broader industry strategy this summer.

Keep ReadingShow less
AAH upgrades ordering portal, making procurement easier for pharmacies

AAH Cascade compares prices and availability across suppliers

AAH Warehouse

AAH upgrades ordering portal to improve product visibility

Leading pharmaceutical wholesaler AAH Pharmaceuticals Ltd has introduced new digital functionalities to AAH Cascade, its independently managed ordering portal, making procurement easier and more cost-effective for pharmacies.

AAH Cascade compares product prices and availability across multiple suppliers, eliminating the need for manual searches.

Keep ReadingShow less
Majority of Brits neglect consistent skincare routine,  survey finds

On average, Brits go to bed without washing their face twice a week.

Photo credit: gettyimages

Skincare: One in five Brits go to bed without washing their face daily, survey finds

Nearly two-thirds of Brits (60 per cent) neglect a consistent skincare routine,with almost one in five going to bed without washing their face daily, according to a new survey by consumer health company Kenvue.

The UK-wide survey of 2,000 people revealed that one-third of respondents (34 per cent) spend five minutes or less on their daily skincare routine. On average, Brits go to bed without washing their face twice a week.

Keep ReadingShow less
Risk of pharmacy closures remains despite record funding uplift

Community pharmacy sector remains in a fragile position as the funding gap is still significant, says CCA.

gettyimages

Pharmacy closures still a risk as funding deal fails to cover costs – warns CCA

The community pharmacy sector has secured the largest funding uplift across the NHS, yet concerns remain that it may not be enough to prevent further closures and service reductions.

Following a six-week consultation with Community Pharmacy England (CPE), the government has approved a £3.073 billion funding package for 2025/26, supplemented by an additional £215 million to support Pharmacy First and other Primary Care Recovery Plan services.

Keep ReadingShow less